Welcome to our dedicated page for Immuneering news (Ticker: IMRX), a resource for investors and traders seeking the latest updates and insights on Immuneering stock.
Immuneering Corporation reports clinical oncology developments centered on Deep Cyclic Inhibitors, a category of cancer medicines the company is developing for durability, tolerability and combinability. Its lead product candidate, atebimetinib (IMM-1-104), is an oral, once-daily Deep Cyclic Inhibitor of MEK being studied across MAPK pathway-driven tumors, including pancreatic cancer.
Recurring updates include survival and safety data from atebimetinib in combination with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer, molecular and circulating tumor DNA analyses tied to MAPK resistance mechanisms, and presentations at oncology meetings such as ASCO and AACR. Company news also covers financial results, R&D spending, pipeline strategy, regulatory-readiness activities and healthcare-conference presentations.
Immuneering , a clinical-stage oncology company, is focused on developing universal-RAS/RAF medicines for cancer patients. The company is recognizing Melanoma Awareness Month by highlighting RAS mutant melanoma as the focus of its Phase 2a clinical study for IMM-1-104. Additionally, they are evaluating melanoma in their Phase 1/2a study of IMM-6-415. Immuneering expects to release initial data from multiple Phase 2a arms in 2024.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.